Month: August 2026

Sixty-four appointments in a matter of months. That was one man's reality after an aggressive prostate cancer diagnosis, and it left him with strong opinions about what helps and what doesn't. His six insights cover the shock of the news, the meaning behind a rising PSA, picking the right doctors, and the value of plain communication. keep reading

Roughly one in ten prostate cancers is diagnosed in men younger than 55, and incidence keeps climbing about 3% a year. Growth rate helps explain why that matters. Tumor doubling times differ by Gleason grade, and one model suggests men diagnosed before 50 get far less warning between tumor onset and clinical detection. keep reading

What if the treatment holding prostate cancer back was quietly working on the heart? A new study using specialized PET/MRI scans followed 43 men on androgen deprivation therapy and found inflammation building in the carotid, iliac, and aortic arteries. Statins and antiplatelet drugs may soften the effect, though researchers say more work is needed. keep reading

A PSA of 2.1 sounds like good news. For a small number of men, it is a disguise. Swedish researchers screened thousands of men and found clinically significant prostate cancer in the low-PSA range, detected only after MRI pointed to a suspicious lesion. Newer risk scores now aim to catch what a single PSA number misses. keep reading

PSA is just a protein. It leaks into the bloodstream from healthy and unhealthy prostate cells alike, which means a high reading can signal cancer or nothing at all. Miami researchers found that men eating the most healthful plant-based diets had the lowest odds of an elevated PSA, and a 2024 study extends that benefit even after treatment. keep reading

Most men treated for early prostate cancer are alive five years later, whatever option they choose. So why do about 1 in 7 look back with regret? The answer has less to do with survival and more to do with side effects nobody prepared them for, and with how the decision got made in the first place. New long-term data adds urgency to that question. keep reading

For decades, a localized prostate cancer diagnosis came with two options: treat the whole gland and accept the side effects, or watch and wait. It was an all-or-nothing choice. Focal therapy changed the math. New 10-year international data shows cancer control comparable to radical prostatectomy, with far less risk to urinary and sexual function. keep reading

Not every prostate cancer patient wants to choose between surgery and surveillance. Transperineal Focal Laser Ablation offers a third path, and it requires far less specialized equipment than MRI-guided ablation does. That makes the procedure shorter, simpler, less costly, and considerably easier for patients to access. keep reading

For localized prostate cancer, the options can feel like two extremes: treat the whole gland and risk lasting side effects, or treat none of it and live with the worry of watching and waiting. Focal therapy sits in between. By destroying just the tumor and a small margin around it, it aims for cancer control close to radical treatment while preserving the quality of life that comes with treating none of the gland. keep reading

Why treat an entire prostate when the trouble usually starts in one spot? That question sits at the heart of focal therapy. For decades the answer was that doctors couldn't see or target the tumor precisely enough. Advances in multiparametric MRI, MRI-guided biopsy, and the index lesion concept finally changed that, opening a middle path between radical treatment and active surveillance. keep reading